Is digoxin compatible with intravenous magnesium sulfate when administered through a common Y‑site?

Y-Site Compatibility: Digoxin and IV Magnesium Sulfate

Digoxin and intravenous magnesium sulfate should NOT be mixed in the same container or administered simultaneously through the same intravenous line. The FDA-approved digoxin label explicitly states that "mixing of digoxin injection with other drugs in the same container or simultaneous administration in the same intravenous line is not recommended" 1.

Key Administration Guidelines

FDA Label Directives (Highest Priority)

The digoxin prescribing information provides clear guidance 1:

• Do not mix digoxin injection with other drugs in the same container
• Do not administer simultaneously in the same IV line
• Digoxin can be administered undiluted or diluted only with:
  • Sterile Water for Injection
  • 0.9% Sodium Chloride Injection
  • 5% Dextrose Injection
• Use at least a 4-fold volume of diluent to prevent precipitation
• Administer over 5 minutes or longer to avoid vasoconstriction

Clinical Context: When These Drugs Are Used Together

Importantly, IV magnesium sulfate is actually recommended as treatment for digoxin-induced ventricular arrhythmias 2. The 2017 AHA/ACC/HRS guidelines state that "intravenous magnesium is often administered if VAs [ventricular arrhythmias] are present" in the context of digoxin toxicity 2. However, this therapeutic combination does not imply Y-site compatibility—they should be given through separate IV access.

Practical Implications

Risk Factors for Incompatibility

• Hypomagnesemia increases digoxin toxicity risk 3, 4, 5, 4, 3, making magnesium repletion clinically important
• Digoxin has a narrow therapeutic window with toxic levels only slightly above therapeutic levels 1
• The combination is frequently needed in ICU settings where IV access is limited

Safe Administration Strategy

1. Use separate IV lines for digoxin and magnesium sulfate
2. If limited vascular access exists, administer sequentially rather than simultaneously
3. Flush the line thoroughly between medications
4. Monitor for signs of precipitation or incompatibility if sequential administration is necessary

Evidence Gaps

The systematic review by Foinard et al. 6 found that physical and chemical compatibility data exist for only 54% of commonly used two-drug combinations in ICUs, with only 9% having chemical stability data. No specific Y-site compatibility studies between digoxin and magnesium sulfate were identified in the provided evidence, which reinforces the conservative approach mandated by the FDA label.

Recent ICU-specific compatibility research 7 emphasizes that concentration-matched data are critical, as compatibility can be concentration-dependent. The absence of such data for this specific combination, combined with the explicit FDA prohibition, makes the conservative approach mandatory.

Critical Caveat

While magnesium sulfate has been studied for Y-site compatibility with other drugs 8, 9, the FDA label prohibition for digoxin supersedes any general compatibility data. The label's blanket restriction against mixing digoxin with other drugs in the same line reflects the drug's narrow therapeutic index and the serious consequences of any physical or chemical incompatibility that could alter drug delivery.